Prevalence of hepatitis B and C virus infections among HIV‑infected patients in a tertiary hospital in North‑Western Nigeria

Nigerian Journal of Basic and Clinical Sciences

Volumn 10, Issue 2, 2013, Pages 76-81

  Hamza, Muhammad ^a,b   Samaila, Adamu Alhaji ^a,b   Yakasai, Ahmad Maifada ^b   Babashani, Musa ^a,b   Borodo, Musa Muhammad ^a,b   Habib, Abdulrazaq Garba ^a,b  

^a BAYERO UNIVERSITY   (Nigeria)

^b AMINU KANO TEACHING HOSPITAL   (Nigeria)

Author keywords

Hepatitis B; Hepatitis C; HIV; Nigeria; prevalence

Indexed keywords

EID: 85034802163     PISSN: 03318540     EISSN: 24889288     Source Type: Journal    
DOI: 10.4103/0331-8540.122765     Document Type: Article

References (27)

1. WHO global report on HIV/AIDS 2011.
2. Uneke CJ, Ogbu O, Inyama PU, Anyanwu GI, Njoku MO, Idoko JH. Prevalence of hepatitis‑B surface antigen among blood donors and human immunodeficiency virus‑infected patients in Jos, Nigeria. Mem Inst Oswaldo Cruz 2005;100:13‑6.
3. Mendes‑Correa MC, Barone AA, Cavalheiro NP, Tengan FM, Guastini C. Prevalence of hepatitis B and C in the sera of patients with HIV infection in São Paulo, Brazil. Rev Inst Med trop S Paulo 2000;42:81‑5.
4. Fainboim H, González J, Fassio E, Martínez A, Otegui L, Eposto M, et al. Prevalence of hepatitis viruses in an anti‑human immunodeficiency virus‑positive population from Argentina. A Multicentre Study. J Viral Hepat 1999;6:53‑7.
5. Koike K, Tsukada K, Yotsuyanagi H, Moriya K, Kikuchi Y, Oka S, et al. Prevalence of coinfection with human immunodeficiency virus and hepatitis C virus in Japan. Hepatol Res 2007;37:2‑5.
6. Sulkowski MS, Moore RD, Mehta SH, Chaisson RE, Thomas DL. HepatitisCandprogressionofHIVdisease.JAMA2002;288:199‑206.
7. Soriano V, Sulkowski M, Bergin C, Hatzakis A, Cacoub P, Katlama C, et al. Care of patients with chronic hepatitis C and HIV coinfection: Recommendations from the HIV‑HCV International panel. AIDS 2002;16:813‑28.
8. Greub G, Ledergerber B, Battegay M, Grob P, Perrin L, Furrer H, et al. Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV‑1 and hepatitis C virus coinfection: The Swiss HIV Cohort Study. Lancet 2000;356:1800‑5.
9. Otegbayo JA, Taiwo BO, Akingbola TS, Odaibo GN, Adedapo KS, PenugondaS,etal.PrevalenceofhepatitisBandCseropositivityina NigeriancohortofHIV‑infectedpatients.AnnHepatol2008;7:152‑6.
10. Adewole OO, Anteyi E, Ajuwon Z, Wada I, Elegba F, Ahmed P, et al. Hepatitis B and C virus co‑infection in Nigerian patients with HIV infection. J Infect Dev Ctries 2009;3:369‑75.
11. Simpore J, Savadogo A, Ilboudo D, Nadambega MC, Esposito M, Yara J, et al. Toxoplasma gondii, HCV, and HBV seroprevalence and co‑infection among HIV‑positive and –negative pregnant women in Burkina Faso. J Med Virol 2006;78:730‑3.
12. Rouet F, Chaix ML, Inwoley A, Msellati P, Viho I, Combe P, et al. HBV and HCV prevalence and viraemia in HIV‑positive and HIV‑negative pregnant women in Abidjan, Cote d’Ivoire: The ANRS 1236 study. J Med Virol 2004;74:34‑40.
13. Brandful JA, Apeagyei FA, Ampofo WK, Adu‑Sarkodie Y, Ansah JE, Nuvor V, et al. Relationship between immunoclinical status and prevalence of viral sexually transmitted diseases among human immunodeficiency virus‑1 seropositive patients in Ghana. Viral Immunol 1999;12:131‑7.
14. Harania RS, Karuru J, Nelson M, Stebbing J. HIV, hepatitis B and hepatitis C coinfection in Kenya. AIDS 2008;22:1221‑2.
15. Mphahlele MJ, Lukhwareni A, Burnett RJ, Moropeng LM, Ngobeni JM. High risk of occult hepatitis B virus infection in HIV‑positivepatientsfromSouthAfrica.JClinVirol2006;35:14‑20.
16. Nagu TJ, Bakari M, Matee M. Hepatitis A, B and C viral co‑infections among HIV‑infected adults presenting for care and treatment at Muhimbili National Hospital in Dar es Salaam, Tanzania. BMC Public Health 2008;8:416.
17. th conference on retroviruses and opportunistic infections, Boston, USA. 2008 abstract 1058.
18. Monforte Ade A, Bugarini R, Pezzotti P, De Luca A, Antinori A, Mussini C, et al., ICONA (Italian Cohort of Naive for Antiretrovirals) Study Group. Low frequency of severe hepatotoxicity and association with HCV co‑infection in HIV positive patients treated with HAART. J Acquir Immune Defic Syndr 2001;28:114‑23.
19. Sulkowski MS, Thomas DL, Mehta SH, Chaisson RE, Moore RD. Hepatotoxicity associated with nevirapine or efavirenz‑containing antiretroviral therapy: Role of hepatitis C and B infections. Hepatology 2002;35:182‑9.
20. Davis LG, Weber DJ, Lemon SM. Horizontal transmission of HBV. Lancet 1989;1:889‑93.
21. Drew JS, London WT, Lustbader ED. Cross‑reactivity between hepatitis B surface antigen and a male associated antigen. Birth Defects Orig Artic Ser 1978;15:91‑101.
22. Lesi OA, Kehinde MO, Oguh DN, Amira CO. Hepatitis B and C infection in Nigerian patients with HIV/AIDS. Nat Postgraduate Med J 2007;14:129‑33.
23. Zhou J, Dore GJ, Zhang F, Lim PL, Chen YM, TREAT Asia HIV ObservationalDatabase.HepatitisBandCvirusco‑infectioninThe TREAT Asia HIV Observational Database. J Gastroenterol Hepatol 2007;22:1510‑8.
24. Iwalokun BA, Hodonu SO, Olaleye BM, Olabisi OA. Seroprevalence and biochemical features of hepatitis B surface antigenemia in patients with HIV 1 –infection in Lagos. Afr J Med Sci 2006;35:337‑43.
25. BenhamouY,BochetM,DiMartinoV,CharlotteF,AzriaF,CoutellierA, et al. Liver fibrosis progression in human immunodeficiency virus and hepatitis C co‑infected patients. Hepatology 1999;30:1054‑8.
26. Rockstroh JK. Influence of viral hepatitis on HIV infection. J Hepatol 2006;44:S25‑7.
27. Sulkowski MS, Thomas DL, Chaisson RE, Moore RD. Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection. JAMA 2000;283:74‑80.